1. Triflusal in Patients with Acute Coronary Syndrome and Acetylsalicylic Acid Hypersensitivity.
- Author
-
Fuertes Ferre G, Pérez Guerrero A, Linares Vicente JA, Jimeno Sánchez J, Alonso-Ventura V, Cubero Saldaña JL, Galache Osuna JG, Andrés Esteban EM, Diarte de Miguel JA, Ortas Nadal MDR, and Casasnovas Lenguas JA
- Subjects
- Aspirin adverse effects, Drug Therapy, Combination, Humans, Platelet Aggregation Inhibitors adverse effects, Retrospective Studies, Salicylates, Treatment Outcome, Acute Coronary Syndrome drug therapy, Percutaneous Coronary Intervention
- Abstract
Background: Acetylsalicylic acid hypersensitivity (ASAH) limits therapeutic options in patients with acute coronary syndrome (ACS), who benefit from dual antiplatelet therapy (DAPT), especially when undergoing stent implantation. Our aim was to evaluate the safety and efficacy of triflusal in patients with ACS and ASAH., Methods and Results: Two-center retrospective study of patients diagnosed with ACS and ASAH from January 1, 2000, to May 1, 2020. Sixty-six patients were treated with triflusal. ASAH was confirmed with tests in 15 patients (22.7%). Forty-nine patients (74.2%) presented history of other drug allergies. Fifty-nine patients (89.4%) underwent stent implantation. DAPT was prescribed for ≥12 months in 54 patients. No adverse reactions to triflusal were reported. During a median follow-up of 5.12 years [IQR 2.7-9.9], rate of cardiovascular (CV) mortality was 6.1%, nonfatal myocardial infarction 12.1%, and ischemic stroke 4.5%. No cases of definite stent thrombosis occurred. Bleeding Academic Research Consortium grade ≥2 was observed in 3 patients during follow-up., Conclusion: In this series of patients presenting with ACS and ASA hypersensitivity, triflusal showed good tolerability and was associated with a low rate of CV and bleeding events., (© 2021 S. Karger AG, Basel.)
- Published
- 2021
- Full Text
- View/download PDF